Chronic lymphocytic leukaemia - ofatumumab (TA202)
Fast, easy summary view of NICE guidance on 'blood and bone marrow cancers'
Ofatumumab for the treatment of chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab
NICE does not recommend ofatumumab for people with chronic lymphocytic leukaemia that is refractory to treatment with two other drugs called fludarabine and alemtuzumab.
NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS. NICE applies special considerations to treatments that can extend the lives of people who are nearing the end of their life.
It was not clear from the evidence whether ofatumumab provides enough benefit to patients to justify its high cost, and it did not qualify for special consideration (because of doubts about the evidence), so NICE did not recommend it.
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: blood and bone marrow cancers
This page was last updated: 14 January 2014
- Web format
- Quick reference guide (PDF)
- Full Guidance (PDF)
- TA202 Ofatumumab ar gyfer lewcemia lymffosytig cronig nad yw'n ymateb mwyach i fludarabine ac alemtuzumab: deall canllawiau NICE (fformat MS Word)
Information for the public
Implementation tools and resources
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.